Erythropoietin

Endogenous Protection of Ischemic Brain

Robert T. Mallet, Myoung Gwi Ryou, Myoung Gwi Ryou

Research output: Chapter in Book/Report/Conference proceedingChapterResearchpeer-review

6 Citations (Scopus)

Abstract

The human brain requires uninterrupted delivery of blood-borne oxygen and nutrients to sustain its function. Focal ischemia, particularly, ischemic stroke, and global ischemia imposed by cardiac arrest disrupt the brain's fuel supply. The resultant ATP depletion initiates a complex injury cascade encompassing intracellular Ca2 + overload, glutamate excitotoxicity, oxido-nitrosative stress, extracellular matrix degradation, and inflammation, culminating in neuronal and astroglial necrosis and apoptosis, neurocognitive deficits, and even death. Unfortunately, brain ischemia has proven refractory to pharmacological intervention. Many promising treatments afforded brain protection in animal models of focal and global ischemia, but failed to improve survival and neurocognitive recovery of stroke and cardiac arrest patients in randomized clinical trials. The culprits are the blood–brain barrier (BBB) that limits transferral of medications to the brain parenchyma, and the sheer complexity of the injury cascade, which presents a daunting array of targets unlikely to respond to monotherapies. Erythropoietin is a powerful neuroprotectant capable of interrupting multiple aspects of the brain injury cascade. Preclinical research demonstrates erythropoietin's ability to suppress glutamate excitotoxicity and intracellular Ca2 + overload, dampen oxidative stress and inflammation, interrupt the apoptotic cascade, and preserve BBB integrity. However, the erythropoietin dosages required to traverse the BBB and achieve therapeutically effective concentrations in the brain parenchyma impose untoward side effects. Recent discoveries that hypoxia induces erythropoietin production within the brain and that neurons, astroglia, and cerebrovascular endothelium harbor membrane erythropoietin receptors, raise the exciting prospect of harnessing endogenous erythropoietin to protect the brain from the ravages of ischemia-reperfusion.

Original languageEnglish
Title of host publicationVitamins and Hormones
PublisherAcademic Press Inc.
Pages197-232
Number of pages36
DOIs
StatePublished - 1 Jan 2017

Publication series

NameVitamins and Hormones
Volume105
ISSN (Print)0083-6729

Fingerprint

Erythropoietin
Brain
Ischemia
Heart Arrest
Brain Ischemia
Glutamic Acid
Stroke
Erythropoietin Receptors
Inflammation
Wounds and Injuries
Neuroprotective Agents
Astrocytes
Brain Injuries
Reperfusion
Endothelium
Extracellular Matrix
Oxidative Stress
Necrosis
Randomized Controlled Trials
Animal Models

Keywords

  • Apoptosis
  • Blood–brain barrier
  • Cardiac arrest
  • Caspase
  • Glutamate
  • Inflammation
  • Matrix metalloproteinase
  • Reactive oxygen species
  • Stroke

Cite this

Mallet, R. T., Ryou, M. G., & Ryou, M. G. (2017). Erythropoietin: Endogenous Protection of Ischemic Brain. In Vitamins and Hormones (pp. 197-232). (Vitamins and Hormones; Vol. 105). Academic Press Inc.. https://doi.org/10.1016/bs.vh.2017.01.002
Mallet, Robert T. ; Ryou, Myoung Gwi ; Ryou, Myoung Gwi. / Erythropoietin : Endogenous Protection of Ischemic Brain. Vitamins and Hormones. Academic Press Inc., 2017. pp. 197-232 (Vitamins and Hormones).
@inbook{5fe8b5c694e84e0280e19899cab4eb63,
title = "Erythropoietin: Endogenous Protection of Ischemic Brain",
abstract = "The human brain requires uninterrupted delivery of blood-borne oxygen and nutrients to sustain its function. Focal ischemia, particularly, ischemic stroke, and global ischemia imposed by cardiac arrest disrupt the brain's fuel supply. The resultant ATP depletion initiates a complex injury cascade encompassing intracellular Ca2 + overload, glutamate excitotoxicity, oxido-nitrosative stress, extracellular matrix degradation, and inflammation, culminating in neuronal and astroglial necrosis and apoptosis, neurocognitive deficits, and even death. Unfortunately, brain ischemia has proven refractory to pharmacological intervention. Many promising treatments afforded brain protection in animal models of focal and global ischemia, but failed to improve survival and neurocognitive recovery of stroke and cardiac arrest patients in randomized clinical trials. The culprits are the blood–brain barrier (BBB) that limits transferral of medications to the brain parenchyma, and the sheer complexity of the injury cascade, which presents a daunting array of targets unlikely to respond to monotherapies. Erythropoietin is a powerful neuroprotectant capable of interrupting multiple aspects of the brain injury cascade. Preclinical research demonstrates erythropoietin's ability to suppress glutamate excitotoxicity and intracellular Ca2 + overload, dampen oxidative stress and inflammation, interrupt the apoptotic cascade, and preserve BBB integrity. However, the erythropoietin dosages required to traverse the BBB and achieve therapeutically effective concentrations in the brain parenchyma impose untoward side effects. Recent discoveries that hypoxia induces erythropoietin production within the brain and that neurons, astroglia, and cerebrovascular endothelium harbor membrane erythropoietin receptors, raise the exciting prospect of harnessing endogenous erythropoietin to protect the brain from the ravages of ischemia-reperfusion.",
keywords = "Apoptosis, Blood–brain barrier, Cardiac arrest, Caspase, Glutamate, Inflammation, Matrix metalloproteinase, Reactive oxygen species, Stroke",
author = "Mallet, {Robert T.} and Ryou, {Myoung Gwi} and Ryou, {Myoung Gwi}",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/bs.vh.2017.01.002",
language = "English",
series = "Vitamins and Hormones",
publisher = "Academic Press Inc.",
pages = "197--232",
booktitle = "Vitamins and Hormones",

}

Mallet, RT, Ryou, MG & Ryou, MG 2017, Erythropoietin: Endogenous Protection of Ischemic Brain. in Vitamins and Hormones. Vitamins and Hormones, vol. 105, Academic Press Inc., pp. 197-232. https://doi.org/10.1016/bs.vh.2017.01.002

Erythropoietin : Endogenous Protection of Ischemic Brain. / Mallet, Robert T.; Ryou, Myoung Gwi; Ryou, Myoung Gwi.

Vitamins and Hormones. Academic Press Inc., 2017. p. 197-232 (Vitamins and Hormones; Vol. 105).

Research output: Chapter in Book/Report/Conference proceedingChapterResearchpeer-review

TY - CHAP

T1 - Erythropoietin

T2 - Endogenous Protection of Ischemic Brain

AU - Mallet, Robert T.

AU - Ryou, Myoung Gwi

AU - Ryou, Myoung Gwi

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The human brain requires uninterrupted delivery of blood-borne oxygen and nutrients to sustain its function. Focal ischemia, particularly, ischemic stroke, and global ischemia imposed by cardiac arrest disrupt the brain's fuel supply. The resultant ATP depletion initiates a complex injury cascade encompassing intracellular Ca2 + overload, glutamate excitotoxicity, oxido-nitrosative stress, extracellular matrix degradation, and inflammation, culminating in neuronal and astroglial necrosis and apoptosis, neurocognitive deficits, and even death. Unfortunately, brain ischemia has proven refractory to pharmacological intervention. Many promising treatments afforded brain protection in animal models of focal and global ischemia, but failed to improve survival and neurocognitive recovery of stroke and cardiac arrest patients in randomized clinical trials. The culprits are the blood–brain barrier (BBB) that limits transferral of medications to the brain parenchyma, and the sheer complexity of the injury cascade, which presents a daunting array of targets unlikely to respond to monotherapies. Erythropoietin is a powerful neuroprotectant capable of interrupting multiple aspects of the brain injury cascade. Preclinical research demonstrates erythropoietin's ability to suppress glutamate excitotoxicity and intracellular Ca2 + overload, dampen oxidative stress and inflammation, interrupt the apoptotic cascade, and preserve BBB integrity. However, the erythropoietin dosages required to traverse the BBB and achieve therapeutically effective concentrations in the brain parenchyma impose untoward side effects. Recent discoveries that hypoxia induces erythropoietin production within the brain and that neurons, astroglia, and cerebrovascular endothelium harbor membrane erythropoietin receptors, raise the exciting prospect of harnessing endogenous erythropoietin to protect the brain from the ravages of ischemia-reperfusion.

AB - The human brain requires uninterrupted delivery of blood-borne oxygen and nutrients to sustain its function. Focal ischemia, particularly, ischemic stroke, and global ischemia imposed by cardiac arrest disrupt the brain's fuel supply. The resultant ATP depletion initiates a complex injury cascade encompassing intracellular Ca2 + overload, glutamate excitotoxicity, oxido-nitrosative stress, extracellular matrix degradation, and inflammation, culminating in neuronal and astroglial necrosis and apoptosis, neurocognitive deficits, and even death. Unfortunately, brain ischemia has proven refractory to pharmacological intervention. Many promising treatments afforded brain protection in animal models of focal and global ischemia, but failed to improve survival and neurocognitive recovery of stroke and cardiac arrest patients in randomized clinical trials. The culprits are the blood–brain barrier (BBB) that limits transferral of medications to the brain parenchyma, and the sheer complexity of the injury cascade, which presents a daunting array of targets unlikely to respond to monotherapies. Erythropoietin is a powerful neuroprotectant capable of interrupting multiple aspects of the brain injury cascade. Preclinical research demonstrates erythropoietin's ability to suppress glutamate excitotoxicity and intracellular Ca2 + overload, dampen oxidative stress and inflammation, interrupt the apoptotic cascade, and preserve BBB integrity. However, the erythropoietin dosages required to traverse the BBB and achieve therapeutically effective concentrations in the brain parenchyma impose untoward side effects. Recent discoveries that hypoxia induces erythropoietin production within the brain and that neurons, astroglia, and cerebrovascular endothelium harbor membrane erythropoietin receptors, raise the exciting prospect of harnessing endogenous erythropoietin to protect the brain from the ravages of ischemia-reperfusion.

KW - Apoptosis

KW - Blood–brain barrier

KW - Cardiac arrest

KW - Caspase

KW - Glutamate

KW - Inflammation

KW - Matrix metalloproteinase

KW - Reactive oxygen species

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=85014160309&partnerID=8YFLogxK

U2 - 10.1016/bs.vh.2017.01.002

DO - 10.1016/bs.vh.2017.01.002

M3 - Chapter

T3 - Vitamins and Hormones

SP - 197

EP - 232

BT - Vitamins and Hormones

PB - Academic Press Inc.

ER -

Mallet RT, Ryou MG, Ryou MG. Erythropoietin: Endogenous Protection of Ischemic Brain. In Vitamins and Hormones. Academic Press Inc. 2017. p. 197-232. (Vitamins and Hormones). https://doi.org/10.1016/bs.vh.2017.01.002